Bristol-Myers grants ARV license for two drugs to Aurobindo Pharma
17 Mar 2006
Aurobindo
Pharma Ltd has been given the license to market Stavudine
and Didanosine, two important anti retro virals by Bristol-Myers
Squibb Company. The license covers 49 countries including
South Africa.
One of the objectives of this license is to increase access of the products for the benefit of the people in the aforesaid territory specifically for the treatment of HIV / AIDS.
Aurobindo Pharma has the largest number of approved products by US FDA for the ARV segment and anchors the management of AIDS by supplying APIs and formulations for most of the anti retro virals.
Stavudine Capsules 30mg and 40mg and Stavudine Oral Solution 1mg / ml are already approved by the US FDA under PEPFAR programme. The US FDA already approves the relevant API and formulation facilities.